Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Soundwill (878 HK): Thoughts On The Latest Scheme Fail

Henlius (2696 HK): LVC Sits On A Blocking Stake. And Me (Maybe) Eating Humble Pie

Henlius (2696 HK): So, When Was The Last Time A PE/VC Outfit Blocked A Deal?

Henlius (2696 HK): LVC Won't Block. Buy Here & On Weakness

Quiddity Advisors

Event-Driven

<ul>
<li>The question was asked in <a href="https://skr.ma/2qNon" target="_blank" rel="noopener">Henlius (2696 HK): So, When Was The Last Time A PE/VC Outfit Blocked A Deal?</a> Well, now we have one as LVC inexplicably <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0122/2025012200662.pdf" target="_blank" rel="noopener">blocked</a>.</li>
<li>It didn’t appear to make economic rationale for LVC to crash the party - knowing they would do so, and not bother to reduce their position accordingly.</li>
<li>In tandem with the <a href="https://www.smartkarma.com/entities/china-traditional-chinese-medicine" target="_blank" data-smartkarma-citation="entities:351:1" rel="noopener">TCM (570 HK)</a> debacle, it sets another bad precedent for future/existing Hong Kong  events. Expect spreads for HK arbs to widen. And Henlius to crater.</li>
</ul>


The question was asked in Henlius (2696 HK): So, When Was The Last Time A PE/VC Outfit Blocked A Deal? Well, now we have one as LVC inexplicably blocked.
It didn’t appear to make economic rationale for LVC to crash the party - knowing they would do so, and not bother to reduce their position accordingly.
In tandem with the TCM (570 HK) debacle, it sets another bad precedent for future/existing Hong Kong  events. Expect spreads for HK arbs to widen. And Henlius to crater.


China Traditional Chinese Medicine (570 HK)

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Henlius (2696)'s Fail Sets (Another) Bad Precedent

Shanghai Henlius Biotech

Henlius (2696)'s Fail Sets (Another) Bad Precedent